Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors—2020 Update
During the last 20 years, chemotherapy has improved survival rates of colorectal cancer (CRC). However, the majority of metastatic cases do not respond to or progress after first line conventional chemotherapy and contribute to the fatalities of patients with CRC. Insights into the immune contexture...
Main Authors: | Gerhard Jung, Daniel Benítez-Ribas, Ariadna Sánchez, Francesc Balaguer |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/11/3520 |
Similar Items
-
Advances of immune checkpoints in colorectal cancer treatment
by: Qinlian Jiao, et al.
Published: (2020-03-01) -
Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?
by: Emmanouil Damilakis, et al.
Published: (2020-04-01) -
Research Progress of Immune Checkpoint Therapy on Colorectal Cancer
by: CAO Qihua, et al.
Published: (2021-03-01) -
The Avastin application in clinical practice in patients with metastatic colorectal cancer: Second interim analysis of the observational AJAX program
by: I V Poddubnaya, et al.
Published: (2014-03-01) -
Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
by: Shima Makaremi, et al.
Published: (2021-08-01)